GILEAD SCIENCES, INC. Earnings Per Share Disclosure
| Year Ended December 31, | ||||||||||||||||||||
| (in millions, except per share amounts) | 2025 | 2024 | 2023 | |||||||||||||||||
| Net income attributable to Gilead | $ | 8,510 | $ | 480 | $ | 5,665 | ||||||||||||||
| Shares used in basic earnings per share attributable to Gilead calculation | 1,244 | 1,247 | 1,248 | |||||||||||||||||
| Dilutive effect of equity-based awards | 11 | 8 | 10 | |||||||||||||||||
| Shares used in diluted earnings per share attributable to Gilead calculation | 1,255 | 1,255 | 1,258 | |||||||||||||||||
| Basic earnings per share attributable to Gilead | $ | 6.84 | $ | 0.38 | $ | 4.54 | ||||||||||||||
| Diluted earnings per share attributable to Gilead | $ | 6.78 | $ | 0.38 | $ | 4.50 | ||||||||||||||
Historical Timeline
| Fiscal Year | Filed | |
|---|---|---|
| 2025 | Feb 24, 2026 | Showing above |
| 2024 | Feb 28, 2025 | |
| 2023 | Feb 23, 2024 | |
| 2022 | Feb 22, 2023 | |
About Earnings Per Share Disclosures
The earnings per share disclosure breaks down the calculation from net income to both basic and diluted EPS, revealing the full impact of a company's capital structure on per-share economics. The reconciliation between basic and diluted share counts exposes how many stock options, RSUs, convertible securities, and warrants are potentially dilutive to existing shareholders.
Key signals: a widening gap between basic and diluted shares indicates growing dilution from equity compensation or convertible instruments. Anti-dilutive securities excluded from the diluted calculation deserve attention — they represent latent dilution that will materialize if the stock price rises. Watch for the effect of share buybacks on per-share metrics: EPS growth driven primarily by repurchases rather than income growth signals weakening fundamentals. Compare year-over-year changes in the diluted share count against equity compensation expense to assess whether management is effectively managing dilution.